Received: 12 June 2019
Accepted: 24 December 2019
First Online: 17 January 2020
Change Date: 31 January 2020
Change Type: Correction
Change Details: Following the publication of this article , the authors reported errors in Figs. 1, 2 and 5. Due to a typesetting error the asterisks denoting significance were missing from the published figures.
Ethics approval and consent to participate
: Three datasets considered in this study were also examined in our previous study [CitationRef removed, CitationRef removed]. The stool data collection was approved by the Cork hospital ethics committee (APC-022 and APC-046).
: Not applicable.
: The authors declare a conflict of interest. We have the following competing interests: this work was supported by Second Genome Inc. which employs and provides stock options to N.R.N, T.W., K.D., S.I., & T.Z.D.. Second Genome Inc. is an independent therapeutics company with products in development to treat liver disorders and other human diseases. A publication announcing the availability of Piphillin analysis for academic use will not affect the value of our therapeutic products. There are no Piphillin patents, products in development, or marketed products to declare.